Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 1/20 | 0.43 |
| ▸ | KDM1A | O60341 | 4/20 | 0.43 |
| ▸ | HTR2A | P28223 | 1/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.40 |
| ▸ | CTSD | P07339 | 1/20 | 0.38 |
| ▸ | SLC6A2 | P23975 | 6/20 | 0.37 |
| ▸ | SLC6A4 | P31645 | 6/20 | 0.37 |
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24065055 | 1.00 | HTR6 (0.43) | HTR6KDM1AHTR2ASIGMAR1CTSD | |
| SCHEMBL6631116 | 1.00 | HTR6 (0.43) | HTR6KDM1AHTR2ASIGMAR1CTSD | |
| SCHEMBL19182923 | 1.00 | HTR6 (0.43) | HTR6KDM1AHTR2ASIGMAR1CTSD | |
| SCHEMBL6631112 | 1.00 | HTR6 (0.43) | HTR6KDM1AHTR2ASIGMAR1CTSD | |
| SCHEMBL3047034 | 1.00 | HTR6 (0.43) | HTR6KDM1AHTR2ASIGMAR1CTSD | |
| Hydrochloric Acid SCHEMBL4199739 | 0.98 | KDM1A (0.46) | HTR6KDM1AHTR2ASIGMAR1CTSD | |
| Hydrochloric Acid SCHEMBL31324603 | 0.98 | KDM1A (0.46) | HTR6KDM1AHTR2ASIGMAR1CTSD | |
| SCHEMBL15375784 | 0.81 | IDO1 (0.49) | SLC6A2SLC6A4SLC6A3CYP2D6 | |
| SCHEMBL19182899 | 0.80 | KDM1A (0.40) | KDM1AHTR2ASIGMAR1SLC6A2SLC6A4 | |
| SCHEMBL20678731 | 0.80 | KDM1A (0.40) | KDM1AHTR2ASIGMAR1SLC6A2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190031599-A1 | INDANE DERIVATIVES AS MGLUR7 MODULATORS | TAKEDA CAMBRIDGE LIMITED (GB) | 2019-01-31 | — | — | US | disclosed |
| WO-2018047983-A1 | INDANE DERIVATIVES USEFUL AS MODULATORS OF MGLUR7 | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-03-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190031599-A1 | INDANE DERIVATIVES AS MGLUR7 MODULATORS | GRM7, GRIN2B, GRM1 | HTR6 171/4885KDM1A 1761/4885HTR2A 155/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.